Ademi LLP is investigating Inari (NASDAQ: NARI) for possible breaches of fiduciary duty and other violations of law in its transaction with the Stryker.
In the transaction, Inari stockholders will receive $80 per share, representing a total fully diluted equity value of approximately $4.9 billion. Inari insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Inari by imposing a significant penalty if Inari accepts a competing bid. We are investigating the conduct of Inari’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.